MITOCHONDRIAL DISORDERS TREATMENT MARKET ANALYSIS
Mitochondrial Disorders Treatment Market: Competitive Landscape
The key players operating in the market are adopting strategic collaborations with research organizations to advance drugs for rare diseases through clinical development. For instance, in February 2018, NeuroVive Pharmaceutical AB in collaboration with Karolinska Institute developed a compound NV556 to treat patients with mitochondrial myopathy. The company is expected to initiate the clinical trials for the compound with the effective outcomes from its preclinical study.
Key players operating in the global mitochondrial disorders treatment market include Centogene AG, GeneDx, Ixchel Pharma, Khondrion BV, Mitobridge, NeuroVive Pharmaceutical AB, Reata Pharmaceuticals Inc., and Stealth Biotherapeutics.
Mitochondrial Disorders Treatment Market Report Snapshots
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients